Zacks Investment Research upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a research report released on Thursday, Zacks.com reports. They currently have $20.00 price target on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other brokerages also recently commented on KURA. HC Wainwright reissued a buy rating and issued a $29.00 price objective on shares of Kura Oncology in a research note on Friday, August 2nd. Citigroup boosted their price objective on shares of Kura Oncology from $18.00 to $25.00 and gave the stock a buy rating in a research note on Friday, May 24th. ValuEngine raised shares of Kura Oncology from a buy rating to a strong-buy rating in a research note on Monday, June 17th. Deutsche Bank started coverage on shares of Kura Oncology in a research note on Thursday, July 18th. They issued a buy rating and a $28.00 price objective for the company. Finally, Cowen reissued a buy rating on shares of Kura Oncology in a research note on Monday, June 17th. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the stock. Kura Oncology presently has an average rating of Buy and a consensus price target of $27.89.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. Equities research analysts predict that Kura Oncology will post -1.61 EPS for the current year.
In other Kura Oncology news, insider Antonio Gualberto sold 18,000 shares of Kura Oncology stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $21.11, for a total value of $379,980.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 11.00% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Kura Oncology by 2.6% in the second quarter. BlackRock Inc. now owns 2,407,038 shares of the company’s stock worth $47,396,000 after purchasing an additional 61,255 shares during the last quarter. Eagle Asset Management Inc. grew its holdings in shares of Kura Oncology by 0.7% during the first quarter. Eagle Asset Management Inc. now owns 2,048,708 shares of the company’s stock valued at $33,988,000 after buying an additional 14,317 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kura Oncology by 23.0% during the second quarter. Vanguard Group Inc. now owns 2,012,548 shares of the company’s stock valued at $39,628,000 after buying an additional 376,172 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Kura Oncology by 12.0% during the second quarter. Victory Capital Management Inc. now owns 1,967,270 shares of the company’s stock valued at $38,736,000 after buying an additional 210,900 shares during the last quarter. Finally, Brown Advisory Inc. purchased a new stake in shares of Kura Oncology during the second quarter valued at $11,799,000. 79.65% of the stock is currently owned by institutional investors and hedge funds.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Story: How is a buy-side analyst different from a sell-side analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.